Gilead Sciences, Inc.

GILDleader

Gilead Sciences is a research-based biopharmaceutical company that revolutionized the treatment of HIV and hepatitis C. Biktarvy has become the most prescribed HIV treatment globally, and the company is expanding aggressively into oncology through its Kite cell therapy division and antibody-drug conjugate platform.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($28.1B)

靜態數據（加載即時財務…）

HIV (Biktarvy, Descovy) (55%)

Oncology (Trodelvy, Yescarta) (18%)

Liver Disease (HCV/HBV) (10%)

Veklury & Other (17%)

業務部門構成與主要客戶

產品詳情

Biktarvy45%

Leading single-tablet HIV regimen combining three antivirals

Veklury (Remdesivir)10%

Antiviral treatment for COVID-19 and emerging viral threats

Trodelvy/Cell Therapy25%

Oncology portfolio including ADCs and CAR-T via Kite Pharma

供應鏈關係

競爭對手

Pfizer Inc.

Antiviral therapies

影響: Competing in antivirals

AbbVie Inc.

Oncology pipeline overlap

影響: Competing in oncology

合作夥伴

Moderna, Inc.

Potential mRNA-based HIV vaccine collaboration

影響: Research partnership

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 Gilead Sciences, Inc. 的 AI 供應鏈分析。

企業資訊

總部

Foster City, California, USA

成立時間

1987

員工人數

18,000+

官網

gilead.com

行業概況 — 제약 / 바이오

行業新聞